Search - tctmd.com

Displaying 161 - 180 of 299

Sort: Relevancy | Date

Presentation TVT 2017

When and How to Use Transcatheter Devices for PVL Closure After TAVR

Presenter: Chet Rihal

June 15, 2017

Presentation TVT 2017

Video-Densitometric Assessment of Aortic Regurgitation: In Vitro Validation, Clinical Prognosis, and Applications

Presenter: Patrick W. Serruys

June 15, 2017

Presentation TVT 2017

Expert Commentary: PVL Assessment and Management When to Post-dilate

Presenter: Rebecca T. Hahn

June 15, 2017

Presentation TVT 2017

Case Tutorial #2: A Case of Managing Para-valvular Regurgitation During TAVR - Case Presentation

Presenter: Omar K. Khalique

June 15, 2017

Presentation TVT 2017

Is Para-valvular Regurgitation After TAVR Still an Important Consideration in 2017?

Presenter: Philippe Pibarot

June 15, 2017

Presentation TVT 2017

TAVR Outcomes for Bicuspid Aortic Valve Disease in Asian Patients

Presenter: Jung-Min Ahn

June 15, 2017

Presentation TVT 2017

Case Outcome

Presenter: Christopher U. Meduri

June 15, 2017

Presentation TVT 2017

Expert Commentary: TAVR Device Selection and CT Sizing for Bicuspid Aortic Valves

Presenter: Didier Tchetche

June 15, 2017

Presentation TVT 2017

Case Tutorial #1: A Case of Bicuspid Aortic Valve Disease With Heavy Leaflet Calcification Case Presentation

Presenter: Christopher U. Meduri

June 15, 2017

Presentation TVT 2017

CT-Based Classification of Bicuspid Aortic Valve Disease: Implications for TAVR Treatment

Presenter: Hasan Jilaihawi

June 15, 2017

Presentation TVT 2017

A Surgeons Perspective of Bicuspid Aortic Valve Disease Anatomic Patterns Favorable for TAVR

Presenter: Mark J. Russo

June 15, 2017

Presentation TVT 2017

Setting the Stage: Achieving Acceptance for TAVR in All Patients With Severe AS

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

June 15, 2017

Presentation SIF 2017

TAVR Will Be Default in Low Risk Patients

Presenter: David L. Brown

March 11, 2017

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Does Newer Equipment Lower Dose? Does Physician Education Help?

Presenter: Stephen Balter

November 01, 2016

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Wilson Y. Szeto

November 01, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Presenter: Niall T. Mulvihill, Michael Mahmoudi

October 31, 2016

Presentation TCT 2016

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Presenter: Niall T. Mulvihill, Hellmuth Weich

October 31, 2016

Advertisement

When and How to Use Transcatheter Devices for PVL Closure After TAVR

Video-Densitometric Assessment of Aortic Regurgitation: In Vitro Validation, Clinical Prognosis, and Applications

Expert Commentary: PVL Assessment and Management When to Post-dilate

Case Tutorial #2: A Case of Managing Para-valvular Regurgitation During TAVR - Case Presentation

Is Para-valvular Regurgitation After TAVR Still an Important Consideration in 2017?

TAVR Outcomes for Bicuspid Aortic Valve Disease in Asian Patients

Case Outcome

Expert Commentary: TAVR Device Selection and CT Sizing for Bicuspid Aortic Valves

Case Tutorial #1: A Case of Bicuspid Aortic Valve Disease With Heavy Leaflet Calcification Case Presentation

CT-Based Classification of Bicuspid Aortic Valve Disease: Implications for TAVR Treatment

A Surgeons Perspective of Bicuspid Aortic Valve Disease Anatomic Patterns Favorable for TAVR

Setting the Stage: Achieving Acceptance for TAVR in All Patients With Severe AS

TAVR Will Be Default in Low Risk Patients

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Does Newer Equipment Lower Dose? Does Physician Education Help?

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Debate: Should All Low-Risk Patients With Severe Aortic Stenosis Who are Suitable Be Allowed to Choose TAVR Rather than Surgical AVR, Without Further Trial Evidence? Con Position

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content